Chapter 38: Management of Anxiety Disorders

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, when you think about a physical injury, like a broken arm or something, there's this comforting expectation of precision, right?

Yeah, absolutely.

You just take an x -ray, you see the jagged white line and the doctor just points at it and says, yep, there it is.

It's broken.

Right.

It's visible.

It's totally binary.

I mean, we treat the fracture, slap a cast on it, and the healing process is, you know, highly predictable.

Exactly.

But then you step into the world of psychiatric pharmacology and suddenly that x -ray machine is just useless.

Yeah, completely useless.

The diagnostic and treatment landscape gets so nuanced because, well, we're treating subjective human experiences.

So if you are listening to this right now, chances are you're a nursing student prepping for a pharmacology exam, or maybe you're getting ready to step onto the floor for clinicals.

Which is terrifying and exciting.

Right.

So consider this your last minute lecture.

Our mission for this deep dive is to unpack Chapter 38 of Lens Pharmacology for Nursing Care, the 12th edition, exactly as it appears in your text.

We are diving deep into the management of anxiety disorders today.

Yeah.

And to really lay the groundwork here, we have to differentiate everyday anxiety from pathological anxiety because, I mean, anxiety is a nearly universal human experience.

Well, for sure we all feel it.

Exactly.

And it manifests through two primary components.

So there's the psychological component, which is, you know, those subjective feelings of fear, apprehension, dread,

uneasiness.

Yeah.

And then there's the somatic or the physical component.

This is when your nervous system kicks into gear.

So we're talking tachycardia, palpitations, trembling,

dry mouth,

sweating, shortness of breath.

Okay.

Let me put that into a framework.

I like to think of normal anxiety as like a functioning fire alarm in a building.

Okay.

I like that.

Right.

Because if there's a real fire, a stressful high -stake situation, like a massive final exam or a near -miss car accident, that alarm is supposed to go off.

It's adaptive.

It keeps us vigilant and preps the body to respond to danger.

Yeah.

And in those acute, situationally appropriate cases, stepping in with a pharmacological intervention isn't just unnecessary.

It can actually be counterproductive to how you cope and perform.

Right.

You want that adrenaline.

But an anxiety disorder is basically like a broken fire alarm.

Yes.

The alarm rings constantly at top volume when there's no smoke anywhere.

Yeah.

Or, I don't know, it triggers a massive building evacuation just because someone lit a single candle.

Exactly.

It becomes persistent, disproportionate, and just profoundly disabling to a person's daily life.

And if you look at the epidemiological data in your textbook,

pathological anxiety is honestly incredibly prevalent.

It really is.

About 25 % of Americans will develop an anxiety disorder at some point.

And there's a significantly higher incidence in women than in men.

And a crucial diagnostic reality here for your nursing practice is the high rate of comorbidity.

The overlap, yeah.

Right.

Depression frequently co -occurs with anxiety disorders.

Because of that, the overarching treatment strategy that Chapter 38 emphasizes relies on a dual approach.

For most patients, combining psychotherapy with drug therapy provides far superior outcomes than just doing one or the other alone.

Okay.

So looking at Table 38 .1 in the text, which maps out the drug classes used across the different disorders, two heavyweight categories really dominate the landscape.

We've got serotonergic reuptake inhibitors or SRIs, which includes your SSRIs and SNRIs and benzodiazepines.

The big two.

Yeah.

But diving into this chart, there's this immediate paradox.

SRIs were fundamentally developed and categorized as antidepressants.

Right.

So if a patient is diagnosed purely with an anxiety disorder and they do not have comorbid depression, handing them an antidepressant seems, I mean, completely counterintuitive.

It totally seems backwards.

Yeah.

But it really comes down to how these drugs alter brain chemistry over time.

So while they were originally marketed for depression, SRIs modulate the neurotransmitter serotonin.

Which does more than just mood.

Exactly.

Serotonin is heavily involved in regulating the neural pathways responsible for fear and worry too.

Because they stabilize those pathways, SRIs are highly effective against anxiety regardless of whether depression is present.

Oh, wow.

Okay.

Yeah.

So consequently, they are the modern first line treatment for all five of the anxiety disorders we're unpacking today.

Benzodiazepines, by contrast, have a much narrower application now.

They're mostly just utilized for generalized anxiety disorder and panic disorder.

So let's look at how these pharmacological tools are actually deployed, starting with generalized anxiety disorder or GAD.

If an anxiety disorder is a broken fire alarm,

GAD is like the chronic low -level hum of the system malfunctioning.

Just this unrelenting background noise of dread.

Yeah.

The clinical hallmark of GAD is unrealistic or excessive anxiety about multiple events or activities.

And crucially, this must persist for six months or longer.

Right.

So we are definitely differentiating GAD from just a few weeks of acute stress.

Exactly.

And of all the anxiety disorders, GAD is the least likely to spontaneously remit.

The symptom profile is really broad.

Psychologically, patients experience tension, hypervigilance, poor concentration.

Somatically, they suffer from chronic muscle tension, trembling, and that autonomic hyperactivity.

Like the cold, clammy hands, the racing heart, the GI distress.

Yep.

All of that.

So for first -line drug therapy, the FDA has approved four specific SRIs.

We have venlafaxine and deloxetine, which are the SNRIs, and then peroxetine and acetylaprim, which are the SSRIs.

Okay.

But the text has a really specific clinical nuance here.

These drugs are highly effective at decreasing the cognitive and psychic symptoms, the constant worrying, but they aren't always quite as effective at eliminating those physical somatic symptoms.

And that nuance absolutely dictates the nursing care plan, right?

Because when a patient presents with GAD, their internal experience is intensely uncomfortable.

They want an immediate off switch.

They want it gone today.

Yeah.

As a nurse, managing their expectations is paramount because the anxiolytic effects of SRIs develop very, very slowly.

Extremely slowly.

But wait, if I'm a patient sitting in a clinic trembling with severe anxiety and you prescribe me a daily pill, I am totally expecting to feel better by dinnertime.

Telling me to wait feels almost cruel.

What is the actual timeline here?

I know it's tough.

Initial responses might just begin to surface after a week of consistent daily dosing, but optimal sustained therapeutic responses, that takes several more weeks to develop.

Wow.

Because this relief relies on long -term neurological adaptation, these medications absolutely cannot be used PRN or as needed.

You can't just pop one on a bad day.

Right.

You cannot take an SSRI only on a Tuesday when you're stressed and expect it to work.

Furthermore, while they don't have the abuse potential of scheduled narcotics, abrupt discontinuation triggers an incredibly uncomfortable withdrawal syndrome, so they absolutely must be tapered.

Okay.

Since SRIs are the first line foundation, I want to look at the first line drug the chapter highlights, which is buspirone.

Ah, yes.

Buspirone.

I always conceptualize buspirone as the decaf anxiety medication.

That's a great way to put it.

Right.

Because it manages the anxiety.

But unlike benzodiazepines, it is emphatically not a central nervous system depressant.

It doesn't cause sedation and it has zero abuse potential, which just makes it incredibly appealing for a huge demographic of patients.

Yeah.

Buspirone is just as effective as benzodiazepines for managing GD, but the mechanism of action is completely different.

It does not bind to GABA receptors.

And because it's not a CNS depressant, it won't intensify the effects of other depressants like alcohol, barbiturates, or other sedating meds.

But it shares that same major disadvantage as the SRIs, right?

It does.

The pharmacokinetics dictate a delayed onset.

Initial effects take a week and it needs several weeks to reach peak efficacy.

So again, completely useless as a PRN medication.

And looking at the nursing implications, the drug and food interactions for buspirone are highly specific.

Like this is prime material for a pharmacology exam.

The text flags ritromycin, ketoconazole, and grapefruit juice.

Yep.

The classic grapefruit juice warning.

Right.

And if I'm understanding the mechanism here, this isn't just a mild interaction.

These specific substances inhibit the CYP3A4 enzyme in the intestines and that is the exact mechanism.

So under normal circumstances, that CYP3A4 enzyme breaks down a large portion of the buspirone before it ever reaches systemic circulation.

But when a patient drinks grapefruit juice, it blocks that enzyme.

Without that metabolic breakdown,

massive amounts of buspirone enter the bloodstream.

We're talking about a five to 13 -fold increase in drug levels.

Oh, wow.

Thirteen times the dose.

Basically, yeah.

And this leads to profound toxicity, which manifests as significant drowsiness and a subjective dysphoria.

Patients often describe it as feeling deeply unsettled, spacey, or just detached from reality.

Yikes.

Okay.

So SRIs and buspirone are the slow, steady, daily therapies.

But inevitably, you know, we'll encounter a patient whose GAD has escalated to a point where they are entirely nonfunctional.

They need immediate stabilization.

This is where benzodiazepines enter the picture as a second line option.

Exactly.

Benzodiazepines like alprizolam or diazepam provide that immediate onset of benefits that SRIs lack.

They work by enhancing the actions of GABA, which is the primary inhibitory neurotransmitter in the brain.

The brain's breaks.

Exactly.

Think of GABA as the brain's natural breaking system.

When GABA binds to its receptors, it opens chloride channels, which hyperpolarizes the neuron and makes it less likely to fire.

Benzodiazepines just amplify this breaking system, rapidly telling the hyperactive neurological circuits to calm down.

But the textbook explicitly demotes them to second line therapy for a multitude of safety reasons.

I mean, they cause pervasive sedation, psychomotor slowing, which increases fall risks and impairs driving.

Huge fall risk, especially in the elderly.

Right.

Plus, there is a documented potential for abuse.

But the most concerning thing to me as a future nurse is the physical dependence.

The text explains that if a patient has been on a benzodiazepine long term for GAD and abruptly stops, the withdrawal syndrome includes severe panic, paranoia, and delirium.

It's awful.

That is terrifying because the withdrawal mimics the exact pathology they were originally trying to escape.

It really creates a treacherous clinical scenario.

Clinicians have to carefully differentiate between a physiological withdrawal reaction and a relapse of the underlying GAD.

To prevent these severe withdrawal symptoms, a patient must be meticulously tapered off a benzo over a period of several months.

Months?

Yeah.

The timeline is critical.

A provider cannot simply cross taper instantly by starting buspirone on a Monday and stopping the benzodiazepine on Tuesday.

Because buspirone takes weeks to exert its effects, it has to be initiated two to four weeks before even beginning the gradual withdrawal of the benzo.

That perfectly illustrates the complexity of managing these timelines.

Okay, now let's contrast the chronic persistent hum of GAD with the sudden explosive nature of a panic attack.

This brings us to panic disorder.

If GAD is background noise, a panic attack is like a jet engine suddenly taking off inside a phone booth.

That's a very vivid analogy, but it's totally accurate.

The pathophysiology shifts dramatically here.

Panic disorder is essentially a severe malfunction of the brain's alarm system.

A panic attack is an abrupt,

unpredictable surge of intense fear that peaks in just a few minutes and usually dissipates within 30 minutes.

And physically, it feels like dying.

It literally mimics a myocardial infarction.

Palpitations, severe shortness of breath, chest pain, a feeling of choking, and just this profound visceral fear of dying or losing control.

A massive percentage of these patients end up in the ER convinced they're having a heart attack.

And the treatment strategy outlined in the chapter is explicitly a two -pronged approach.

The data shows that combining drug therapy with cognitive behavioral therapy, or CBT, yields the absolute best results.

Yes.

Because the pharmacology suppresses the physiological attacks, but the CBT is essential for addressing the behavioral fallout.

Like when a patient experiences a terrifying panic attack at a grocery store, their natural instinct is to just stop going to the grocery store.

And over time, that avoidance behavior spirals into agoraphobia, where they might become entirely housebound.

Exactly.

So the drugs create a neurological safety net so the patient can actually engage in the CBT.

For drug therapy, SSRIs are the definitive first line choice.

The FDA approved fluoxetine, proxetine, and sertraline.

Regular daily administration decreases the frequency and intensity of the spontaneous attacks, and crucially, it reduces that anticipatory anxiety.

The constant fear of when the next one will hit.

Exactly.

But reading through the safety considerations, I noticed a paradox that feels like a classic trick question for a nursing exam.

The text explicitly states that SSRIs, the very drugs used to treat panic disorder, can actually increase anxiety early in treatment.

Yep, they sure can.

Wait, if my patient is already suffering from debilitating panic attacks, handing them a medication that chemically exacerbates their anxiety seems like malpractice.

Why does this happen?

I know, it sounds crazy.

It relates to the brain's initial sensitivity to neurotransmitter changes.

When you suddenly block the reuptake of serotonin, there is an immediate surge of serotonin in the synaptic cleft.

And before the brain's receptors have time to downregulate and adapt to this new environment, that surge can be super overstimulating, leading to increased agitation and anxiety.

So how do we handle that?

To mitigate this, the nursing action requires meticulous dosing.

Patients with panic disorder are exquisitely sensitive, so you must initiate treatment with unusually low doses.

For example, peroxetine and fluoxetine are started at just 10 mg a day, and sertraline at 25 mg.

Once the brain begins to adapt, the provider slowly titrates the dosage up to a standard maintenance level.

Okay, that makes sense.

But if a patient is crawling out of their skin with panic, and the SSRIs aren't effective yet, my instinct as a nurse is to reach for a benzodiazepine for relief.

But looking at the second -line options and the massive safety alert box in the text, that feels like walking into a trap.

It is a significant clinical risk.

Second -line options include tricyclic antidepressants or TCA's like imipramin.

Now TCA's are highly effective, but they carry a huge burden of adverse effects.

They block muscarinic receptors, causing anticholinergic effects like severe dry mouth, blurred vision, urinary retention.

And they are dangerous in overdoses, right?

Extremely.

In an overdose scenario, TCA's affect cardiac sodium channels, causing fatal dysrhythmias.

Given the high comorbidity of anxiety and depression, handing a potentially suicidal patient a highly lethal medication is a major contraindication.

Which brings us back to benzodiazepines like alprazolam or clonazepam.

They offer that rapid immediate suppression of panic.

But the text safety alert highlights that because panic patients are already so hypersensitized to anxiety, the withdrawal anxiety from stopping a benzo can be absolutely intolerable.

The rebound panic is fierce.

Yeah.

Therefore, tapering isn't just recommended, it is mandatory, and it must occur over incredibly long extended periods to keep the patient stable.

Right.

Now, moving along the spectrum of these conditions, Chapter 38 transitions to Obsessive Compulsive Disorder, or OCD.

Here, the presentation changes from the spontaneous, unpredictable physiological explosions of panic to an anxiety that is tethered to a relentless, inescapable, internal cognitive loop.

Yeah, the text divides OCD into two distinct components.

First, there are the obsessions.

These are intrusive, unwanted, and highly distressing thoughts or mental images.

Like an overwhelming fear of contamination or an agonizing, repeated, doubt -like being unable to shake the thought the stove was left on.

Right.

And second are the compulsions.

These are the repetitive physical behaviors or mental acts driven by the obsessions.

The patient washes their hands until the skin breaks down or drives home to check the stove 20 times.

And the diagnostic criteria specify that this loop must consume at least one hour a day and cause marked distress or functional impairment.

And the management of OCD places a massive emphasis on behavioral therapy.

The specific modality utilized is exposure and response prevention.

The therapist exposes the patient to the triggering stimulus -like touching a doorknob and actively prevents them from executing their compulsive ritual, like washing their hands.

Which sounds agonizing.

It is an excruciating process for the patient, but neurologically, it forces the brain to learn that the anxiety will eventually subside without the compulsion.

On the pharmacological side, SSRIs are the only recognized first -line drugs for OCD.

The textbook lists six specific agents.

Fluoxetine, fluvoxamine, sertraline peroxetine, sitalopram, and acintalopram.

But examining the pharmacokinetics, there is a crucial timeline shift that nursing students have to memorize.

We establish that SSRIs take a few weeks to manage GAD.

But for OCD, the timeline changes drastically.

Oh, it stretches significantly.

For OCD, beneficial effects develop incredibly slowly, requiring several months of continuous daily therapy to reach maximal efficacy.

Waiting months for relief from an internal mental prison requires immense patient education.

If a nurse doesn't actively encourage compliance and explain the timeline, the patient will inevitably abandon the medication after a month, assuming it has failed.

Absolutely.

Furthermore, the required duration of treatment is substantial.

Guidelines recommend that therapy for an initial episode of OCD should continue for an absolute minimum of one year before any attempt is made to discontinue the drug.

A full year.

At least.

And even with a slow taper, the relapse rate upon withdrawal is staggering.

Clinical estimates range from 23 % up to 90%.

Wow, 90%.

Yeah, so consequently, for many patients who experience repeated relapses, lifelong pharmacological therapy becomes necessary.

For a very small subset of patients with severe treatment -resistant OCD, surgical interventions like deep brain stimulation are explored, but that's an absolute last resort.

Okay, so those first three disorders, GAD, Panic, and OCD, are driven primarily by internal misfires.

But what happens when the trigger is externalized?

Not as a physical danger, but as the perceived judgment of the people around you.

This brings us to social anxiety disorder.

Right.

Previously categorized as social phobia, social anxiety disorder is an intense, irrational, and persistent fear of being scrutinized, judged, embarrassed, or humiliated by others.

When the individual is exposed to the feared social situation, their autonomic nervous system triggers intense somatic symptoms.

Perfuse blushing, stuttering, sweating, visible tremors.

And the functional impairment is profound.

Completely.

This disorder can derail a person's life, preventing a brilliant student from attending college classes, or stopping a capable adult from advancing in their career just due to an inability to endure meetings.

The text provides a vital diagnostic distinction here, dividing the disorder into two forms.

Generalized, where the individual experiences paralyzing fear in nearly all social situations, and performance only, where the fear is strictly limited to specific actions, like public speaking or performing on stage.

If I'm reviewing a patient's chart, how does the pharmacological strategy shift based on which form of social anxiety they have?

It all comes down to matching the drug's pharmacokinetic profile to the patient's specific lifestyle demands.

So if a patient suffers from generalized social anxiety, they are confronting their triggers constantly, every single day.

They require a systemic, steady state intervention.

Therefore, daily SSRIs, specifically peroxetine and sertraline, are the first line choice.

When the timeline is still slow.

Yeah, the timeline remains slow, initial effects take about 4 weeks, and optimal therapeutic benefits are seen in 8 to 12 weeks.

But looking at the performance only criteria, the approach has to change.

I mean, if my patient is a violinist who only experiences this anxiety once a month during a symphony performance,

prescribing a daily SSRI that alters their resting brain chemistry 365 days a year is massive overkill.

Precisely why alternative interventions are utilized.

For performance only anxiety, the patient requires immediate PRN, or as needed, relief.

Benzodiazepines like clonazepam or alprazolam can be prescribed for immediate use prior to the event.

Alternatively, providers frequently utilize beta blockers, specifically propranolol.

Okay, wait.

Using a beta blocker is a fascinating application.

We typically study propranolol in the cardiovascular chapters for managing hypertension.

How does a blood pressure medication solve a psychiatric issue?

Well, the mechanism is entirely physical.

Performance anxiety creates a surge of adrenaline that binds to beta receptors, causing a racing heart, sweating, and tremors.

By taking a relatively small dose of propranolol, 10 to 80 mg, 1 to 2 hours before the performance, the drug blocks those beta receptors.

Oh wow.

It stops the autonomic hyperactivity cold.

The heart rate stays steady and the hands don't shake.

Because it doesn't cross the blood -brain barrier to cause sedation in the same way benzodiazepine does, the performer maintains complete mental clarity while the physical symptoms of panic are neutralized.

That is a brilliant bridge between cardiovascular and psychiatric pharmacology.

It really is.

And that brings us to the final disorder covered in chapter 38,

post -traumatic stress disorder, or PTSD.

Now, the previous disorders often lack a single defining point of origin.

PTSD is the exact opposite.

The pathology is forged in the fire of a specific external historical trauma.

Yes.

The diagnostic criteria for PTSD require exposure to a traumatic event that involves a legitimate threat of serious injury or death, eliciting an intense psychological reaction of fear, helplessness, or horror.

This encompasses experiences like military combat, severe physical or sexual assault, natural disasters, or surviving a terrorist attack.

The resulting clinical symptoms fall into three core buckets.

Let me break those down.

First,

patients experience persistent re -experiencing of the event through intrusive memories, vivid nightmares, or severe flashbacks where they feel the trauma is occurring again.

Second, there is a profound avoidance of any reminders of the event, which often manifests alongside a generalized emotional numbing or detachment from loved ones.

Third, they live in a persistent state of hyperarousal, exhibiting an exaggerated startle response, angry outbursts, and severe insomnia.

And the management of PTSD is highly structured.

The clinical practice guidelines released jointly by the Department of Veterans Affairs and the Department of Defense heavily emphasize psychotherapy as the primary intervention.

Specifically, trauma -focused therapies like prolonged exposure therapy are utilized.

In these controlled environments, patients repeatedly reimagine the traumatic events, which over time strips the memories of their visceral power.

Additionally, stress inoculation training helps patients develop concrete coping mechanisms for when their triggers are activated in the real world.

When we pivot to the pharmacology for PTSD, the therapeutic options are surprisingly narrow compared to the broad applications we saw in GED or panic disorder.

Currently, only two SSRIs hold FDA approval as first -line treatments for PTSD,

peroxetine, and sertraline.

Just those two.

But if you're taking a pharmacology exam, you really need to pay close attention to the specific exclusions your textbook lists.

The text explicitly states that current evidence does not support monotherapy with bupropion, buspirone, trazonone, or benzodiazepines for PTSD.

And understanding those exclusions requires looking at the evidence base.

For instance, prescribing a benzodiazepine might seem logically sound for a patient suffering from severe hyperarousal and insomnia.

However,

clinical trials demonstrate that benzodiazepines do not effectively treat the core symptoms of PTSD.

In fact, they interfere with the patient's ability to engage in trauma -focused exposure therapy by blunting emotional processing.

Plus, they carry an incredibly high risk of substance use disorder, which is already a significant comorbidity in the PTSD population.

Knowing why a drug is contraindicated is just as vital as knowing its therapeutic uses.

Absolutely.

So as we wrap up Chapter 38, let's synthesize the broader narrative.

Across the varied presentations of generalized anxiety, panic disorder, OCD,

social anxiety, and PTSD,

the central pharmacological backbone is the use of SSRIs and SNRIs.

They are the slow, steady, long -term solution.

Right.

They alter the neurological landscape over weeks and months to provide sustainable relief without the risks of severe physical dependence.

Benzodiazepines, conversely, represent the fast, risky interventions.

They are powerful tools for rapid stabilization in acute GAD or panic disorder, but their mechanism of action demands immense respect and caution due to the severe risks of CNS depression, abuse, and life -threatening withdrawal syndromes.

It's all about knowing exactly how your tools function, not just what they do, which highlights a vital point for every nursing student listening to this.

Consider how deeply a patient's compliance and ultimately their recovery depends entirely on your ability to educate them.

It's huge.

If a patient doesn't understand the delayed onset of an SSRI or busperone, they will stop taking it because they assume it's broken.

If they aren't educated on the severe withdrawal risks of a benzodiazepine, they might just flush their pills down the toilet to detox and end up in the emergency room with a massive rebound panic attack.

Exactly.

The pharmacology is entirely useless if the nursing education fails.

Understanding the mechanisms, the timelines, and the precise patient teaching points is what transforms these chemical compounds into actual healing.

You are the one holding the manual on how to guide these patients through their treatments safely.

Thank you so much for studying with us today and letting us help you unpack this complex chapter.

From all of us on the last -minute lecture team, good luck on your nursing pharmacology exams.

You've got this.